S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:TCON

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

$2.07
+0.19 (+10.11%)
(As of 08/10/2022 04:16 PM ET)
Add
Compare
Today's Range
$1.83
$2.15
50-Day Range
$1.30
$2.02
52-Week Range
$1.24
$4.49
Volume
167,426 shs
Average Volume
97,973 shs
Market Capitalization
$41.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
418.1% Upside
$10.00 Price Target
Short Interest
Healthy
0.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.05mentions of TRACON Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$1.17 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.24) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

520th out of 1,108 stocks

Biological Products, Except Diagnostic Industry

80th out of 175 stocks

TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on TRACON Pharmaceuticals in a report on Saturday. They issued a "sell" rating for the company.

TRACON Pharmaceuticals Stock Down 1.1 %

TRACON Pharmaceuticals stock traded down $0.02 during trading hours on Wednesday, reaching $1.88. 12,658 shares of the company's stock were exchanged, compared to its average volume of 97,513. The firm's 50 day simple moving average is $1.71 and its 200 day simple moving average is $2.13. TRACON Pharmaceuticals has a twelve month low of $1.24 and a twelve month high of $4.49. The firm has a market capitalization of $38.07 million, a PE ratio of -1.02 and a beta of 1.48.

TRACON Pharmaceuticals (NASDAQ:TCON - Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.07). During the same period in the prior year, the company earned ($0.33) EPS. Analysts anticipate that TRACON Pharmaceuticals will post -1.24 EPS for the current year.

Insider Transactions at TRACON Pharmaceuticals

In related news, major shareholder Opaleye Management Inc. acquired 841,989 shares of the business's stock in a transaction dated Tuesday, June 21st. The shares were bought at an average price of $1.31 per share, with a total value of $1,103,005.59. Following the transaction, the insider now directly owns 3,776,589 shares of the company's stock, valued at $4,947,331.59. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased 870,349 shares of company stock valued at $1,149,698 in the last 90 days. 3.09% of the stock is currently owned by corporate insiders.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

Tracon: Q4 Earnings Snapshot
Tracon Pharmaceuticals Q4 2021 Earnings Preview
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings
11/03/2021
Today
8/10/2022
Next Earnings (Confirmed)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+383.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,670,000.00
Pretax Margin
-9,559.54%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$0.60 per share

Miscellaneous

Free Float
19,626,000
Market Cap
$41.92 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 58)
    Ph.D., CEO, Pres & Director
    Comp: $827.53k
  • Mr. Scott B. Brown CPA (Age 41)
    M.S., Chief Financial Officer
    Comp: $459.21k
  • Mr. Mark C. Wiggins M.B.A. (Age 66)
    Chief Bus. Officer
    Comp: $506.25k
  • Ms. Bonne Adams (Age 45)
    Exec. VP of Clinical Operations
  • Mr. Shahe Garabedian
    Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo (Age 67)
    Chief Medical Officer
  • Mr. Ya Huang
    Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D.
    Pharmd Mba, Sr. VP of Regulatory Affairs













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares.
View TCON analyst ratings
or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2022?

2 Wall Street analysts have issued 1 year price objectives for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 418.1% from the stock's current price.
View analysts price targets for TCON
or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2022?

TRACON Pharmaceuticals' stock was trading at $2.77 at the start of the year. Since then, TCON stock has decreased by 30.3% and is now trading at $1.93.
View the best growth stocks for 2022 here
.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 138,600 shares, a decrease of 15.4% from the June 30th total of 163,800 shares. Based on an average daily volume of 81,700 shares, the days-to-cover ratio is currently 1.7 days.
View TRACON Pharmaceuticals' Short Interest
.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our TCON earnings forecast
.

How can I listen to TRACON Pharmaceuticals' earnings call?

TRACON Pharmaceuticals will be holding an earnings conference call on Wednesday, August 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.06. During the same quarter last year, the company earned ($0.38) EPS.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.93.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $39.09 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-28,670,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.